Biotech & Health Tech
AbbVie bets up to $1.47B on Nxera's gut-targeting IBD program
AbbVie is licensing Nxera Pharma’s EP4 receptor agonist program for $100 million upfront, with up to $1.37 billion at stake in development and commercial milestones. Through its UK subsidiary, Tokyo-based Nxera will hand over global ...
AbbVie is licensing Nxera Pharma’s EP4 receptor agonist program for $100 million upfront, with up to $1.37 billion at stake in development and commercial milestones. Through its UK subsidiary, Tokyo-based Nxera will hand over global ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗